Background The REFINE study examined the efficacy and safety of adding topical corticosteroid therapy to etanercept when stepping down from the initial dose of etanercept to the maintenance dose. Clinical responses were shown to
Introduction
Etanercept is a tumour necrosis factor (TNF) blocker that is approved for the treatment of moderate to severe plaque psoriasis and other autoimmune diseases. 1 The recommended initial dose of etanercept for adult patients with psoriasis is 50 mg administered twice weekly (BIW) 3 or 4 days apart for 12 weeks followed by a maintenance dose of 50 mg once weekly (QW). REFINE, the Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg QW plus as Needed topical agent vs. Etanercept 50 mg BIW in patients with moderate to severe plaque psoriasis, was designed to evaluate the efficacy and safety of adding topical corticosteroid therapy as required to clear to etanercept when patients step down from the initial dose to the maintenance dose. Results from REFINE showed that response to etanercept, as measured by improvements in Psoriasis Area and Severity Index (PASI), was similar in patients who used topical therapies as required to clear with etanercept at 50 mg QW and those who received etanercept at 50 mg BIW. 2 Patient-reported outcomes (PROs) are commonly used in clinical trials to understand the patient's perspective. PROs can be used to assess health-related quality of life (HRQoL), impacts and burdens of disease and treatment satisfaction. In patients with moderate to severe plaque psoriasis, PRO measures generally correlate with clinical outcomes. 3, 4 We now report the results of PROs used to measure HRQoL using the Dermatology Life Quality Index (DLQI), 5 treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM) 6 and health resources utilization (HRU) using the Economic Implications of Psoriasis Patient Questionnaire 7 for patients enrolled in REFINE.
Materials and methods

Study design
REFINE was a phase 3b, multicentre, open-label study and has been described previously. 2 Briefly, all patients enrolled in the study received etanercept 50 mg BIW for the first 12 weeks of the study. Patients were then randomized (1:1) to either remain on etanercept 50 mg BIW or to etanercept 50 mg QW with topical therapies used as required to achieve a static physician global assessment of 0 (clear) or 1 (almost clear) for an additional 12 weeks. Topical agents included hydrocortisone 2.5%, betamethasone valerate 0.1%, betamethasone dipropionate 0.05%, clobetasol 0.05%, calcitriol, or calcipotriol plus betamethasone dipropionate 0.05% and were selected by the investigator. Change in topical agent was allowed.
Patients
To be eligible, patients had stable moderate to severe plaque psoriasis for ≥ 6 months, psoriasis-affected body surface area (BSA) ≥ 10%, PASI score ≥ 10, and qualified as a candidate for systemic therapy or phototherapy. Patients could not have guttate, erythrodermic or pustular psoriasis or significant concurrent medical conditions.
Outcome measures
For this analysis, PRO measures included the DLQI, the TSQM and the Economic Implications of Psoriasis Patient Questionnaire. The DLQI is a validated, 10-question, self-reported questionnaire to evaluate the patient's perception of the impact of psoriasis on HRQoL. 5 The DLQI is rated on a 4-point Likert scale (0 = not at all to 3 = very much). The highest possible total score for the DLQI is 30, and higher scores indicate more severe impact on HRQoL. The TSQM is a validated measure of the major dimensions of patients' satisfaction with medicine. 6 The TSQM comprises 13 items that assess treatment effectiveness (three items), convenience (three items), side-effects (four items) and global satisfaction (three items). Higher scores on the TSQM indicate greater levels of satisfaction. The Economic Implications of Psoriasis Patient Questionnaire evaluates healthcare visits, assistance with daily activities, employment, productivity at work, domestic activities and out-of-pocket expenses. PASI assessments for efficacy, reported previously for REFINE, 2 were also used in the analyses of PROs.
Statistical considerations
This analysis was descriptive and no comparative testing between treatment arms was performed. Missing data were imputed using the last observation carried forward. Exploratory analyses to assess the correlations of the TSQM and DLQI with efficacy as measured by PASI score were performed. Multivariate models were fit at baseline, week 12, and week 24, adjusting for treatment at week 24 and stratification factors of body mass index (BMI) and prior use of TNF blockers for psoriasis. No adjustment was made for multiplicity. All P-values are descriptive.
Results
Patients
The patient population of REFINE has been described previously. 2 Briefly, 310 patients enrolled in the study, 144 were randomized to etanercept 50 mg BIW, 143 were randomized to etanercept 50 mg QW plus topical therapy and 23 patients discontinued from the study before week 12 and were therefore not randomized to further treatment. The patient population was 88% white, 65% were males and the mean [standard deviation (SD)] age was 45 (14) years. 1a) . Change from baseline in mean DLQI total score (SD) to week 24 was 10.7 (7.8) for the etanercept group and 9.9 (6.9) for the etanercept + topical group (Table 1) . DLQI and PASI outcomes at week 12 and week 24 were slightly correlated, with r 2 values of 0.26 and 0.23, respectively, whereas changes from baseline in DLQI and PASI were less correlated with r 2 values of 0.10 and 0.11. There was no evidence of any interaction with the treatments or stratification factors. Patients with a DLQI score of 0 or 1 at week 12 or week 24 had greater PASI improvements than those with higher DLQI scores (Fig. 1b) .
DLQI results
Mean
TSQM results
Mean TSQM scores for effectiveness, convenience, side-effects and global satisfaction were similar between treatment groups at baseline (Fig. 2 ). Mean TSQM scores for effectiveness ( correlation between convenience or side-effects and PASI improvement from baseline to weeks 12 and 24 was observed (P > 0.1). Prior use of a TNF blocker was not statistically significant (P > 0.05). Patients with BMI ≥ 30 kg/m 2 at baseline had significantly higher (P < 0.05) average effectiveness and satisfaction scores at weeks 12 and 24 and higher average convenience score at week 24 than patients with baseline BMI < 30 kg/m 2 .
Specifically, overall satisfaction at week 24 differed for patients by treatment arm and PASI outcome. The opportunity to use a topical agent seemed to improve a patient's overall satisfaction regardless of PASI improvement. In addition, overall satisfaction was high for patients randomized to etanercept alone who also had improvement in PASI relative to those with less PASI improvement (Fig. 3) .
Economic Implications of Psoriasis Patient Questionnaire results
Most patients in both treatment arms responded with 0 (none) to the following items in the questionnaire: number of visits to physician's office or urgent care clinic; number of visits to any healthcare professional (including nurse practitioner, physician assistant, psychologist, naturopath, acupuncturist or chiropractor); number of home visits by a healthcare professional; number of times that the patient paid another person for household chores; and number of hours that a friend or family member had to take time off from work to provide care or transportation to the patient. Employment status (full-time, part-time, unemployed, or retired) and hours missed from work were similar at baseline, week 12, and week 24 in both treatment arms ( Table 2 ). The percentage of patients who reported that their psoriasis affected their productivity while working and ability to perform daily activities 'Not at all' was greater at weeks 12 and 24 than at baseline in both treatment arms. Out-of-pocket expenses were highly variable for both treatment arms; most patients had no out-of-pocket costs (minimum, first quartile, and median values were 0) but some had high costs (Fig. 4) . Median costs were similar between treatment arms, and were lower at week 12 and week 24 than at baseline (excluding two patients who had > $10 000 in unknown non-drug expenses).
Discussion
Results The correlation between PASI improvement and PRO improvement is also consistent with findings from other studies. 4, 9 In a systematic review of 13 randomized, controlled trials of patients treated for their psoriasis, agents that were associated with a 75% improvement in PASI score (PASI 75) or better response to treatment were also associated with significant improvements in DLQI scores (r 2 = 0.898). 4 Similarly, in an analysis of data from two clinical trials of adalimumab in patients with plaque psoriasis (N = 1469), the percentage of patients with DLQI score of 0 was statistically higher for patients with PASI 90 to PASI 100 response compared with patients with lower PASI responses (P < 0.0001). 9 Correlations between effectiveness and global satisfaction subscales, but not convenience and side-effects subscales, of the TSQM with PASI improvements in our study were also observed in a cross-sectional study of systemic and topical therapies for moderate to severe plaque psoriasis. 10 This study tested a 'real-world' strategy of using topical therapies to maintain clinical improvements while the dose of etanercept was reduced. 11, 12 A limitation of the study was the provision of drugs (both etanercept and topical) to the patients at no cost, which may have introduced a bias towards using the topical therapies. Additionally, the duration of treatment with topical therapies was only 12 weeks; a longer duration may result in loss of efficacy as adherence to topical therapies may decrease with time. 13, 14 While the cost of QW etanercept and topical may be a less costly option compared with BIW etanercept, access to etanercept via Canadian public and private drug plans is generally very good, and the cost of higher dose of etanercept may be covered. The analyses of efficacy and PRO data from REFINE were based on a non-inferiority trial design (without statistical testing); long-term hypothesis-testing clinical studies of biologic therapies used in combination with topical therapies with PROs as the primary endpoint are warranted.
In conclusion, measures of HRQoL, including DLQI and TSQM, were numerically similar in patients who stayed on etanercept 50 mg BIW and those who received etanercept 50 mg QW plus topical therapies when used as required to clear. Economic implications of psoriasis treatment, including out-ofpocket expenses, were similar between patients who remained on etanercept monotherapy and those who used concomitant topical therapies.
